3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
60
Lymphoma
56
Leukemia, Myeloid, Acute
51
Leukemia
50
Lymphoma, Non-Hodgkin
48
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46
Hodgkin Disease
36
Myelodysplastic Syndromes
28
Lymphoma, Large B-Cell, Diffuse
27
Breast Neoplasms
24
Lymphoma, Mantle-Cell
23
Neuroblastoma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Burkitt Lymphoma
17
Lymphoma, Follicular
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Central Nervous System Neoplasms
13
Lymphoma, Large-Cell, Immunoblastic
12
Sarcoma
11
Neoplasms, Plasma Cell
11
Brain Neoplasms
11
Recurrence
10
Lymphoma, B-Cell, Marginal Zone
10
Neoplasms
9
Hematologic Neoplasms
9
Congenital Abnormalities
9
Myeloproliferative Disorders
8
Leukemia, Myelomonocytic, Chronic
8
Leukemia, Biphenotypic, Acute
8
Graft vs Host Disease
8
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT01186224
2025-03-17
PHANTASTIC
University of Liverpool
Phase NA
Completed
60 enrolled